Ken Griffin Pacira Bio Sciences, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,600 shares of PCRX stock, worth $439,332. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,600
Previous 22,300
16.59%
Holding current value
$439,332
Previous $554,000
19.86%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding PCRX
# of Institutions
257Shares Held
51.2MCall Options Held
289KPut Options Held
130K-
Black Rock Inc. New York, NY8.01MShares$189 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.41MShares$128 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.4MShares$56.6 Million0.08% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.25MShares$53.2 Million0.04% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.15MShares$50.8 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.08B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...